What does Bremelanotide do? Benefits and evidence

Vyleesi contains bremelanotide, approved for distressing low desire across situations and partners in women before menopause who previously had normal desire. Two large placebo-controlled trials found modest desire and distress improvements, with no clear increase in satisfying sexual events. Nausea and temporary blood pressure rises are the main concerns. Online PT-141 powders and sprays are different products.

• Vyleesi is approved for distressing low sexual desire in women before menopause, when other illnesses, medicines or relationship problems don't explain it. (Drug label)
• In two large trials, women had modest gains in desire and less distress, though the number of satisfying sexual events did not rise. (Studied in a trial)
• One man reported stronger libido and erections; others report a better sexual response when pairing it with tadalafil. (Reported by users)

Uses in the sources

• Vyleesi is FDA-approved for acquired, generalized HSDD in premenopausal women when other illnesses, medicines and relationship problems do not explain it. (Drug label) (source)
• Early trials studied erections and female arousal. A later male nasal trial has an expression of concern. These uses are outside US approval. (Studied in a trial) (source)
• Short inpatient trials studied appetite and weight. A tirzepatide combination trial has no posted results; no weight-loss indication is approved. (Studied in a trial) (source)